Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;19(7):e70112.
doi: 10.1111/crj.70112.

Causal Associations Between Cystatin and Lung Cancer: A Two-Sample Mendelian Randomization Study

Affiliations

Causal Associations Between Cystatin and Lung Cancer: A Two-Sample Mendelian Randomization Study

Chunling Zhang et al. Clin Respir J. 2025 Jul.

Abstract

Introduction: The cystatin family is particularly relevant in lung cancer research due to its links to inflammation, protease balance, and tumor progression. Although population-based studies have documented associations between cystatin and lung cancer, causal relationships remain undetermined.

Methods: Based on genomic statistics of seven different cystatins and three subtypes of lung cancer, we conducted a two-sample Mendelian randomization (MR) study. The inverse-variance weighted (IVW) method was the main approach for causality estimation. The weighted median, simple mode, weighted mode, and MR-Egger regression methods were further employed to validate the main findings. In the sensitivity analysis, horizontal pleiotropy was assessed by MR-Egger regression and Cochran's Q test. MR-PRESSO and Radial MR methods were used to identify heterogeneity and remove outliers.

Results: Genetically predicted Cystatin 8 was causally associated with squamous cell lung carcinoma (OR = 1.062, 95% CI: 1.004-1.124, p = 0.035). No causal relationships were found for genetically predicted cystatin 8, -B, -D, -F, or -M with squamous cell lung carcinoma, lung adenocarcinoma, and NSCLC. However, outliers were identified between Cystatin D, -M, and -F using MR-PRESSO and Radial MR. After the removal of outliers, the association between Cystatin D and lung adenocarcinoma turned significant (OR = 1.178, 95% CI: 1.023-1.358, p = 0.023). Sensitivity analyses confirmed the robustness of main results after outliers removal.

Conclusion: Genetically predicted Cystatin 8 was causally associated with squamous cell lung carcinoma. Future population-based studies are required to substantiate these results.

Keywords: Mendelian randomization; causal correlation; cystatin; lung adenocarcinoma; non‐small cell lung cancer; squamous cell lung carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart of the study design.
FIGURE 2
FIGURE 2
The causal relationships between Cystatin 8 and cell lung cancer using different MR methods. Each panel represents the causal estimates Cystatin 8 for (A) lung adenocarcinoma, (B) squamous cell lung carcinoma, and (C) non‐small cell lung cancer. The slope of each line corresponds to the causal estimates for each method. Individual SNP effects on the outcome (represented by points and vertical lines) against their effects on the exposure (represented by points and horizontal lines) are delineated in the background.

Similar articles

References

    1. Rodak O., Peris‐Díaz M. D., Olbromski M., Podhorska‐Okołów M., and Dzięgiel P., “Current Landscape of Non‐Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy,” Cancers 13 (2021): 4705. - PMC - PubMed
    1. Woenckhaus M., Klein‐Hitpass L., Grepmeier U., et al., “Smoking and Cancer‐Related Gene Expression in Bronchial Epithelium and Non‐Small‐Cell Lung Cancers,” Journal of Pathology 210 (2006): 192–204. - PubMed
    1. Sui Q., Liang J., Hu Z., et al., “Genetic and Microenvironmental Differences in Non‐Smoking Lung Adenocarcinoma Patients Compared With Smoking Patients,” Translational Lung Cancer Research 9 (2020): 1407–1421. - PMC - PubMed
    1. Li C., Lei S., Ding L., et al., “Global Burden and Trends of Lung cancer Incidence and Mortality,” Chinese Medical Journal 136 (2023): 1583–1590. - PMC - PubMed
    1. Leiter A., Veluswamy R. R., and Wisnivesky J. P., “The Global Burden of Lung Cancer: Current Status and Future Trends,” Nature Reviews Clinical Oncology 20 (2023): 624–639. - PubMed

MeSH terms